Accuray Incorporated Announces HSR Clearance in Acquisition of TomoTherapy
SUNNYVALE, Calif., April 26, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced the expiration of the mandatory, pre-merger waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, in connection with the previously announced acquisition of TomoTherapy Incorporated (NASDAQ: TOMO).
"The satisfaction of this condition represents a significant step toward the completion of the transaction and moves us one step closer to bringing together two best-in-class technologies to create the premier radiation oncology company and further improve cancer care for patients," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray.
The transaction is expected to close in June or July of 2011 and is subject to approval by TomoTherapy's shareholders and other customary closing conditions. For more information regarding this transaction, please visit: www.accuraytomotherapy.com.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 222 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com